NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
MWN-AI** Summary
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) cancers, is set to host an investor conference call on March 4, 2026, at 6:00 a.m. Pacific Time (9:00 a.m. Eastern Time). This call will provide an update on the Phase 1 dose-escalation segment of its NEO212-01 clinical trial. This trial is centered around NeOnc's proprietary bioconjugated temozolomide (TMZ) platform, designed for oral administration to patients grappling with CNS malignancies.
The management team will present key insights from the trial, covering safety and toxicity data as well as pharmacokinetic findings and observations from the dose-escalation evaluations. Participating in the call will be esteemed professionals from the Company's Scientific Advisory Board, including Dr. Henry S. Friedman of Duke University and Dr. Alexandra Miller of NYU Langone Health.
NeOnc’s ambitious NEO™ drug development platform is geared towards overcoming the significant challenge of the blood-brain barrier, and its proprietary chemotherapy agents have shown encouraging results in both laboratory and clinical settings, particularly for malignant gliomas. Currently, NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II trials with FDA Fast-Track and Investigational New Drug (IND) status, bolstered by an extensive patent portfolio licensed from the University of Southern California.
Investors and interested parties can access the live webcast of the conference call through the company’s investor website. As NeOnc continues to advance its therapeutic candidates, this conference call represents a crucial opportunity for stakeholders to gauge the progress and prospects of its promising oncology pipeline.
MWN-AI** Analysis
As NeOnc Technologies (Nasdaq: NTHI) prepares to host its investor conference call on March 4, 2026, market participants should focus on the implications of the initial data from the Phase 1 dose-escalation trial of its innovative NEO212-01 therapy. The conference is crucial for investors, given the heightened interest surrounding CNS cancer therapeutics and the ongoing challenges posed by the blood-brain barrier.
Investors should keenly analyze the safety and toxicity data presented during the call, as regulatory approval heavily depends on these findings. The outcomes may significantly influence market sentiment and price action, particularly if early results indicate a favorable safety profile and promising pharmacokinetics for NEO212.
NeOnc's proprietary bioconjugated temozolomide platform is crucial to its competitive advantage. Given that CNS cancers often exhibit resistance to conventional therapies, any indication of efficacy could lead to increased investor confidence and possibly drive shares higher in the coming weeks. Monitoring the response from physicians and oncology experts during the call will also provide valuable insights into market reception and potential uptake post-commercialization.
Additionally, consider how NeOnc’s licensing agreements, particularly the extensive patent portfolio from the University of Southern California, position the company favorably within the industry. The exclusivity until 2038 offers a solid foundation for future revenue generation, potentially mitigating risks for investors.
Lastly, keep an eye on broader market conditions, particularly within the biotech sector, as sentiment can shift quickly based on regulatory developments and news regarding competitor therapies. The NTHI stock price could see volatility around the investor call, thus careful timing for entry or exit positions should be considered. Investors are advised to approach with caution, balancing potential upside with inherent risks in clinical-stage investments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CALABASAS, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced today announced that it will host an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time.
During the call, members of the NeOnc management team and independent members of the Company’s Scientific Advisory Board (SAB) will present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial, evaluating NeOnc’s proprietary bioconjugated temozolomide (TMZ) platform in an oral formulation for patients with CNS malignancies.
The discussion will include an update on the Phase 1 dose-escalation portion of the NEO212-01 clinical trial, including safety and toxicity data, dose-escalation observations, pharmacokinetic findings, and planned regulatory next steps.
Featured Participants:
- Dr. Henry S. Friedman, MD – Deputy Director, Preston Robert Tisch Brain Tumor Center, Duke University; Independent Member, NTHI Scientific Advisory Board
- Dr. Alexandra Miller, MD – Chief Neuro-oncology, Brain Tumor Program, NYU Langone Health; Independent Member, NTHI Scientific Advisory Board
- NTHI Management Team:
- Amir Heshmatpour – Chief Executive Officer, Executive Chairman and President
- Dr. Thomas C. Chen, MD, PhD – Chief Medical Officer and Chief Scientific Officer
- Dr. Josh Neman, PhD – Chief Clinical Officer
- Keithly Garnett – Chief Financial Officer
Conference Call Details:
- Date: March 4, 2026
- Time: 6:00 a.m. PT / 9:00 a.m. ET
- Webcast: A live webcast can be accessed at: https://www.webcaster5.com/Webcast/Page/3151/53708 or by visiting https://investors.neonc.com
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.?
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit https://neonc.com
Important Cautions Regarding Forward Looking Statements?
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated. We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
Investor Contact:?
James Carbonara?
Hayden IR?
(646)-755-7412
FAQ**
What are the key safety and toxicity findings from the initial data of the NEO212-01 clinical trial by NeOnc Technologies Holdings Inc. NTHI that will be discussed during the March 4, 2026, conference call?
How does NeOnc Technologies Holdings Inc. NTHI plan to address any dose-escalation observations made in the Phase 1 trial of their bioconjugated temozolomide platform?
Can you elaborate on the regulatory next steps that NeOnc Technologies Holdings Inc. NTHI intends to pursue after the Phase 1 dose-escalation data is presented on March 4, 2026?
What competitive advantages does NeOnc Technologies Holdings Inc. NTHI's proprietary NEO™ drug development platform offer in the treatment of CNS malignancies compared to existing therapies?
**MWN-AI FAQ is based on asking OpenAI questions about NeOnc Technologies Holdings Inc. (NASDAQ: NTHI).
NASDAQ: NTHI
NTHI Trading
-2.15% G/L:
$9.775 Last:
17,465 Volume:
$9.90 Open:
